Bessemer Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.85M | Sell |
45,473
-3,851,493
| -99% | -$308M | ﹤0.01% | 713 |
|
|
2025
Q4 | $372M | Buy |
3,896,966
+993,753
| +34% | +$97.4M | 0.57% | 32 |
|
|
2025
Q3 | $283M | Sell |
2,903,213
-16,588
| -0.6% | -$1.72M | 0.43% | 47 |
|
|
2025
Q2 | $314M | Buy |
2,919,801
+2,899,653
| +14,392% | +$293M | 0.51% | 43 |
|
|
2025
Q1 | $2.03M | Sell |
20,148
-683
| -3% | -$68.8K | ﹤0.01% | 473 |
|
|
2024
Q4 | $1.86M | Sell |
20,831
-2,881
| -12% | -$254K | ﹤0.01% | 654 |
|
|
2024
Q3 | $1.99M | Buy |
23,712
+5,623
| +31% | +$443K | ﹤0.01% | 655 |
|
|
2024
Q2 | $1.39M | Buy |
18,089
+1,064
| +6% | +$77.9K | ﹤0.01% | 595 |
|
|
2024
Q1 | $1.17M | Buy |
17,025
+2,906
| +21% | +$187K | ﹤0.01% | 651 |
|
|
2023
Q4 | $817K | Sell |
14,119
-4,338
| -24% | -$232K | ﹤0.01% | 699 |
|
|
2023
Q3 | $975K | Buy |
18,457
+3,554
| +24% | +$186K | ﹤0.01% | 630 |
|
|
2023
Q2 | $806K | Buy |
14,903
+4,593
| +45% | +$240K | ﹤0.01% | 690 |
|
|
2023
Q1 | $516K | Sell |
10,310
-467
| -4% | -$22K | ﹤0.01% | 716 |
|
|
2022
Q4 | $499K | Sell |
10,777
-1,245
| -10% | -$53.9K | ﹤0.01% | 731 |
|
|
2022
Q3 | $465K | Sell |
12,022
-9,013
| -43% | -$362K | ﹤0.01% | 746 |
|
|
2022
Q2 | $784K | Buy |
21,035
+589
| +3% | +$24K | ﹤0.01% | 613 |
|
|
2022
Q1 | $905K | Buy |
20,446
+12,033
| +143% | +$521K | ﹤0.01% | 501 |
|
|
2021
Q4 | $358K | Buy |
8,413
+979
| +13% | +$41.1K | ﹤0.01% | 717 |
|
|
2021
Q3 | $322K | Sell |
7,434
-2,973
| -29% | -$132K | ﹤0.01% | 665 |
|
|
2021
Q2 | $444K | Buy |
10,407
+2,124
| +26% | +$89.4K | ﹤0.01% | 608 |
|
|
2021
Q1 | $320K | Buy |
8,283
+1,203
| +17% | +$45.5K | ﹤0.01% | 649 |
|
|
2020
Q4 | $255K | Sell |
7,080
-3,479,297
| -100% | -$125M | ﹤0.01% | 691 |
|
|
2020
Q3 | $133M | Buy |
3,486,377
+367,132
| +12% | +$14.1M | 0.39% | 76 |
|
|
2020
Q2 | $110M | Buy |
3,119,245
+312,986
| +11% | +$11.3M | 0.35% | 85 |
|
|
2020
Q1 | $91.6M | Sell |
2,806,259
-134,851
| -5% | -$5.27M | 0.37% | 78 |
|
|
2019
Q4 | $133M | Sell |
2,941,110
-1,398,517
| -32% | -$58.5M | 0.43% | 70 |
|
|
2019
Q3 | $177M | Buy |
4,339,627
+26,495
| +0.6% | +$1.12M | 0.63% | 40 |
|
|
2019
Q2 | $185M | Buy |
4,313,132
+64,394
| +2% | +$2.48M | 0.62% | 44 |
|
|
2019
Q1 | $163M | Buy |
4,248,738
+4,244,722
| +105,695% | +$162M | 0.63% | 48 |
|
|
2018
Q4 | $142K | Buy |
4,016
+1,634
| +69% | +$59.3K | ﹤0.01% | 1069 |
|
|
2018
Q3 | $92K | Sell |
2,382
-542
| -19% | -$18.9K | ﹤0.01% | 1135 |
|
|
2018
Q2 | $96K | Sell |
2,924
-6,597
| -69% | -$199K | ﹤0.01% | 1125 |
|
|
2018
Q1 | $260K | Sell |
9,521
-767
| -7% | -$20.8K | ﹤0.01% | 962 |
|
|
2017
Q4 | $255K | Buy |
10,288
+2,305
| +29% | +$63.6K | ﹤0.01% | 969 |
|
|
2017
Q3 | $233K | Buy |
7,983
+5,402
| +209% | +$149K | ﹤0.01% | 1031 |
|
|
2017
Q2 | $72K | Buy |
2,581
+1,597
| +162% | +$42.4K | ﹤0.01% | 1239 |
|
|
2017
Q1 | $24K | Sell |
984
-229
| -19% | -$5.57K | ﹤0.01% | 1424 |
|
|
2016
Q4 | $26K | Buy |
1,213
+229
| +23% | +$5K | ﹤0.01% | 1483 |
|
|
2016
Q3 | $23K | Hold |
984
| – | – | ﹤0.01% | 1338 |
|
|
2016
Q2 | $23K | Sell |
984
-2,302
| -70% | -$49.8K | ﹤0.01% | 972 |
|
|
2016
Q1 | $62K | Sell |
3,286
-1,016
| -24% | -$17.8K | ﹤0.01% | 874 |
|
|
2015
Q4 | $79K | Buy |
4,302
+3,876
| +910% | +$69.5K | ﹤0.01% | 880 |
|
|
2015
Q3 | $7K | Buy |
+426
| New | +$7.28K | ﹤0.01% | 1270 |
|
Other funds holding BSX
VCM
VPM
Bessemer Group's BSX Position: Q1 2026 in Review
Bessemer Group reduced its Boston Scientific (BSX) stake by 99% in Q1 2026, selling an estimated $308M and leaving 45,473 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #713.
Bessemer Group first reported a position in BSX in Q3 2015 and has held it in 43 quarters since. The position peaked at $372M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Bessemer Group held 45,473 shares of Boston Scientific worth $2.85M as of Q1 2026.
- Bessemer Group sold 3,851,493 Boston Scientific shares in Q1 2026, an estimated $308M.
- Boston Scientific made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #713 holding.
- Bessemer Group first reported a position in Boston Scientific in Q3 2015 and has held it in 43 quarters since.
- Bessemer Group's Boston Scientific position peaked at $372M in Q4 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.